Clinical Trial Update: Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) [Phase 1]

View source ↗

Summary

This update covers a completed Phase I study evaluating the combination of panobinostat and bortezomib in relapsed and/or refractory Mantle Cell Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• Panobinostat (Panobinostat)

Snippet

Sponsor: Anand Jillella | Conditions: Mantle Cell Lymphoma | Phase 1 | Status: COMPLETED